Bristol-Myers Squibb Company (BMY)
| Market Cap | 97.36B |
| Revenue (ttm) | 47.64B |
| Net Income (ttm) | 5.42B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.67 |
| PE Ratio | 17.91 |
| Forward PE | 7.32 |
| Dividend | $2.48 (5.18%) |
| Ex-Dividend Date | Apr 4, 2025 |
| Volume | 12,788,031 |
| Open | 48.05 |
| Previous Close | 47.95 |
| Day's Range | 47.73 - 48.60 |
| 52-Week Range | 39.35 - 63.33 |
| Beta | 0.39 |
| Analysts | Hold |
| Price Target | 58.93 (+23.18%) |
| Earnings Date | Jul 25, 2025 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $58.93, which is an increase of 23.18% from the latest price.
News
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
Bristol Myers CEO explains why he's spending billions on BioNTech deal
Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ann...
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
Christopher Boerner, CEO of Bristol Myers Squibb, said Monday that the company's $11 billion cancer drug partnership with BioNTech could be "the next new frontier in the treatment of cancer." The comp...
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
Christopher Boerner, Bristol Myers CEO, joins 'Squawk on the Street' to discuss the company's recent partnership with Biontech, the cost of the deal and much more.
Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race
Shares of BioNTech SE were soaring in early Monday trading, after Bristol Myers Squibb Co. made an $11.1 billion splash in the rapidly growing new cancer-drug game.
BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb
BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech's BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.
Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , on an experimental cancer drug, in a deal that could eventually exceed $11 b...
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
MAINZ, Germany & PRINCETON, N.J.--(BUSINESS WIRE)--BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody.
Bristol-Myers Squibb Company (BMY) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY) Bernstein 41st Annual Strategic Decisions Conference May 28, 2025 3:30 PM ET Company Participants Chris Boerner - Chief Executive Officer & Chairman Conference...
Bristol-Myers Squibb's Painful Pullback Has Triggered Richer Dividend Story - Upgrade To Buy
Bristol Myers Squibb's much needed correction has brought the stock back to earth, nearer to its 1Y means while triggering the expanded forward dividend yields. Its dividend investment thesis appears ...
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference.
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for the Subcutaneous Formulation of Opdivo (nivolumab) Across Multiple Solid Tumor Indications.
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
Bristol-Myers Squibb Company appears deeply undervalued, despite business headwinds and revenue declines from legacy products facing generic competition. The market is already pricing in revenue and E...
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
I reiterate my buy rating on Bristol-Myers, seeing significant undervaluation despite persistent weak technicals and sector underperformance. BMY's strong earnings beats, high free cash flow yield, an...
Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
Despite socio-economic challenges and pressure from the generic versions of Revlimid and Abraxane, Bristol-Myers Squibb Company's financial position continues to improve. It raised its 2025 diluted EP...
When It Rains Gold, Put Out The Bucket: 2 Wonderful Income Bargains
Focus on high-quality, dividend-paying stocks with temporary setbacks, offering both value and income for patient investors. Bristol-Myers Squibb is deeply undervalued, carries a 5.3% yield, strong pr...
Avoid These Dividend Disasters Before It's Too Late
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline.
Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' May Dividend Dogs
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge div...
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference.
Buy These 2 Beaten Down Stocks Now Before They Rally
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headw...
5 Dirt-Cheap Dividends Paying Up To 7.6%
Is it time to buy the dip on these cheap dividends—which by the way yield between 5.3% and 7.6%?
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo for.